Recent discussions on X about Enovis Corporation (ENOV) have been ignited by the company’s presentation at the Baird Global Healthcare Conference on September 10, 2025. Many users are focusing on the strategic growth initiatives outlined by the company, with particular interest in how Enovis plans to navigate operational challenges like tariff impacts and product delays. The conversation reflects a mix of curiosity and scrutiny as stakeholders assess the potential impact on future performance.
Posts on X also highlight a keen interest in the financial outlook shared during the conference, with some expressing optimism about the emphasis on organic growth. Others, however, are raising questions about the hurdles that could slow progress, creating a dynamic debate around the stock’s trajectory. This ongoing dialogue keeps the community engaged as they await further updates on execution.
Note: This discussion summary was generated from an AI condensation of post data.
Enovis Corporation Insider Trading Activity
Enovis Corporation insiders have traded $ENOV stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ENOV stock by insiders over the last 6 months:
- DANIEL A PRYOR (EVP, Strategy & Business Dev.) purchased 10,000 shares for an estimated $289,000
- DAMIEN MCDONALD (Chief Executive Officer) purchased 6,457 shares for an estimated $199,973
- BRADLEY J TANDY (SVP and Chief Legal Officer) purchased 3,200 shares for an estimated $100,512
- PHILLIP BENJAMIN (BEN) BERRY (SVP, Chief Financial Officer) purchased 2,500 shares for an estimated $74,275
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Enovis Corporation Hedge Fund Activity
We have seen 171 institutional investors add shares of Enovis Corporation stock to their portfolio, and 173 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 6,206,566 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $194,637,909
- DORSEY ASSET MANAGEMENT, LLC added 2,553,180 shares (+inf%) to their portfolio in Q2 2025, for an estimated $80,067,724
- BLACKROCK, INC. added 1,765,671 shares (+24.7%) to their portfolio in Q2 2025, for an estimated $55,371,442
- AMERICAN CENTURY COMPANIES INC added 1,212,365 shares (+34.4%) to their portfolio in Q2 2025, for an estimated $38,019,766
- DIAMOND HILL CAPITAL MANAGEMENT INC removed 1,091,133 shares (-58.3%) from their portfolio in Q2 2025, for an estimated $34,217,930
- ARTEMIS INVESTMENT MANAGEMENT LLP removed 696,118 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,830,260
- STATE STREET CORP added 592,505 shares (+31.3%) to their portfolio in Q2 2025, for an estimated $18,580,956
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Enovis Corporation Analyst Ratings
Wall Street analysts have issued reports on $ENOV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 08/08/2025
- UBS issued a "Buy" rating on 08/08/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
- Needham issued a "Buy" rating on 08/07/2025
- JMP Securities issued a "Market Outperform" rating on 05/09/2025
To track analyst ratings and price targets for Enovis Corporation, check out Quiver Quantitative's $ENOV forecast page.
Enovis Corporation Price Targets
Multiple analysts have issued price targets for $ENOV recently. We have seen 6 analysts offer price targets for $ENOV in the last 6 months, with a median target of $52.0.
Here are some recent targets:
- Vik Chopra from Wells Fargo set a target price of $41.0 on 08/08/2025
- Danielle Antalffy from UBS set a target price of $57.0 on 08/08/2025
- Caitlin Cronin from Canaccord Genuity set a target price of $58.0 on 08/08/2025
- Mike Matson from Needham set a target price of $49.0 on 08/07/2025
- Vijay Kumar from Evercore ISI Group set a target price of $46.0 on 07/08/2025
- David Turkaly from JMP Securities set a target price of $55.0 on 05/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
